Prostate radiotherapy and the risk of secondary rectal cancer-a meta-analysis
- PMID: 35037077
- DOI: 10.1007/s00384-021-04075-6
Prostate radiotherapy and the risk of secondary rectal cancer-a meta-analysis
Abstract
Purpose: Radiotherapy is being used increasingly in the treatment of prostate cancer. However, ionising radiation may confer a small risk of a radiation-induced secondary malignancy. We aim to assess the risk of rectal cancer following pelvic radiotherapy for prostate cancer.
Methods: A search was conducted of the PubMed/MEDLINE, EMBASE and Web of Science databases identifying studies reporting on the risk of rectal cancer following prostatic radiotherapy. Studies must have included an appropriate control group of non-irradiated prostate cancer patients. A meta-analysis was performed to assess the risk of prostatic radiotherapy on subsequent rectal cancer diagnosis.
Results: In total, 4757 articles were screened with eight studies meeting the predetermined criteria. A total of 796,386 patients were included in this meta-analysis which showed an increased odds ratio (OR) for subsequent rectal cancer in prostate cancer patients treated with radiotherapy compared to those treated by non-radiotherapy means (OR 1.45, 1.07-1.97, p = 0.02).
Conclusion: These findings confirm that prostate radiotherapy significantly increases the risk of subsequent rectal cancer. This risk has implications for treatment selection, surveillance and patient counselling. However, it is crucial that this information is presented in a rational and comprehensible manner that does not disproportionately frighten or deter patients from what might be their most suitable treatment modality.
Keywords: Pelvic radiotherapy; Prostate cancer; Radiation-induced secondary malignancy (RISM); Radiotherapy (RT); Rectal cancer; Second primary malignancy (SPM).
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics CA Cancer J Clin. 2021 Jan;71(1):7–33. https://doi.org/10.3322/caac.21654 . Epub 2021 Jan 12. Erratum in: CA Cancer J Clin. 71(4):359. PMID: 33433946
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 (Epub 2021 Feb 4 PMID: 33538338)
-
- Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE (2016) ProtecT Study Group. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 13;375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220 . Epub. PMID: 27626136
-
- Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/s... , Accessed July 2021.
-
- American Cancer Society ‘Cancer Facts & Figures (2010): Special Section’. Cancer Statistics Center. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts... Accessed July 27th 2021.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
